E. Scott Toner
Keine laufenden Positionen mehr
Profil
E.
Scott Toner worked as a Senior Director-Marketing at Reata Pharmaceuticals, Inc. from 2011 to 2012, and as an Executive Director-Marketing at AMAG Pharmaceuticals, Inc. from 2007 to 2010.
He also worked as a Director at the American Association of Kidney Patients, Inc. and as a Senior Vice President-Commercial at Proteon Therapeutics, Inc. In addition, he worked as a Vice President-Sales & Marketing at OPKO Health, Inc. from 2014 to 2015.
Toner holds an MBA degree from Drexel University and an undergraduate degree from Ithaca College.
Ehemalige bekannte Positionen von E. Scott Toner
| Unternehmen | Position | Ende |
|---|---|---|
| OPKO HEALTH, INC. | Vertrieb & Marketing | 01.01.2015 |
| REATA PHARMACEUTICALS, INC. | Vertrieb & Marketing | 01.12.2012 |
| AMAG PHARMACEUTICALS, INC. | Vertrieb & Marketing | 01.10.2010 |
| PROTARA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| American Association of Kidney Patients, Inc. | Direktor/Vorstandsmitglied | - |
Ausbildung von E. Scott Toner
| Drexel University | Masters Business Admin |
| Ithaca College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OPKO HEALTH, INC. | Health Services |
| Private Unternehmen | 4 |
|---|---|
Proteon Therapeutics, Inc.
 Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
| American Association of Kidney Patients, Inc. |
